Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEGI.L Regulatory News (EGI)

  • There is currently no data for EGI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

21 Jun 2016 07:39

RNS Number : 7815B
Electrical Geodesics, Inc
21 June 2016
 

Electrical Geodesics, Inc.

 

AGM Results

 

 

EUGENE, OREGON, US, 21 June 2016 - Electrical Geodesics, Inc. ("EGI" or the "Company"), a leading neurodiagnostic medical technology company, today announces that all of the resolutions set out in the Company's Notice of Annual General Meeting (the "Meeting") issued to stockholders on 4 May 2016 were passed by stockholders at the Meeting held in Eugene at 9.30 PST yesterday. The Annual Report and Accounts for the year ended 31 December 2015 were also received by the meeting.

 

Don Tucker, CEO of EGI, addressed the meeting briefly, summarising the information on the progress of EGI set out within the 2015 Annual Report. He added: "We will provide detailed comment on current trading early in July with an update on our first six months operations. Our major development projects are progressing well and we believe we can deliver new products to the market in the near term in time to meet our sales targets for 2016."

 

Proxy Voting Results

 

Proxy and actual voting results in respect of Ordinary Resolutions 1 to 4 are shown below. Votes were received from holders of 21,188,186 shares representing 77% of the issued share capital.

 

RESOL-UTION

PROXY

VOTES

FOR

VOTES

PRESENT

FOR

TOTAL VOTES

FOR

 

%

 

VOTES

AGAINST

 

 

%

VOTES

WITHHELD

 

%

1.a

19,396,523

874,997

20,271,520

95.7%

916,666

4.3%

0

0%

1.b

19,396,523

874,997

20,271,520

95.7%

916,666

4.3%

0

0%

1.c

19,396,523

874,997

20,271,520

95.7%

 

916,666

4.3%

0

0%

1.d

19,396,523

874,997

20,271,520

95.7%

916,666

4.3%

0

0%

1.e

19,396,523

874,997

20,271,520

95.7%

 

916,666

4.3%

0

0%

2

 

19,396,523

874,997

20,271,520

95.7%

916,666

4.3%

0

0%

3

19,396,523

874,997

20,271,520

95.7%

916,666

4.3%

0

0%

4

20,313,189

874,997

21,188,186

100%

0

0%

0

0%

 

Ordinary Resolutions

1.a To reappoint Don Tucker as a director

1.b To reappoint Ann Bunnenberg as a director

1.c To reappoint Christine Soden as a director

1.d To reappoint John Brown as a director

1.e To reappoint Raymond Englander as a director

2. To re-appoint Peterson Sullivan LLP as auditors of the Company.

3. To authorise the Directors of the Company to determine the remuneration of the auditors.

4. To amend the Electrical Geodesics, Inc., 2013 Equity Incentive Plan to increase the number of shares of Common Stock that may be issued under that plan from 1,711,415 shares to 1,926,800.

 

Copies of all resolutions and all documents referred to above are available on the Company's website at www.egi.com. 

For more information contact:

 

EGI

 

US: Ann Bunnenberg

+1 541 687 7962

 

 

 

 

 

 

Peel Hunt LLP (NOMAD and Broker)

+44 (0) 20 7418 8900

James Steel, Oliver Jackson

 

 

 

About EGI

Founded in 1992, EGI designs, develops and commercialises a range of non-invasive neurodiagnostic products used to monitor and interpret brain activity based on its proprietary dense array electroencephalography ("dEEG") platform technology. The Company's technology uses up to 256 sensors, providing much higher resolution brain activity data compared to conventional 8 or 16 channel EEG and is used in medical, clinical and research settings in a diverse range of applications including important areas such as the diagnosis and monitoring of epilepsy, neurosurgical planning, sleep assessment, and many others.

 

EGI's dense array technology capitalizes on the Company's unique Hydrocel Geodesic Sensor Net which allows faster, easier, and more convenient placement of many EEG sensors in an even distribution over the entire scalp, providing more accurate and precise diagnosis and measurement. EGI's technology is now widely used in neuroscience research laboratories and is becoming more commonly used in clinics, care centers, and hospitals around the world. Data is measured and visualised using EGI's proprietary amplifier technology and software, providing a complete, advanced, high-resolution EEG platform. The Company's products are compatible with multiple diagnostic and imaging technologies, including magnetic resonance (MR) imaging, functional MRI (fMRI), and magneto-encephalography (MEG).

 

In April 2013 EGI commenced trading on the London Stock Exchange AIM market under the symbol EGI.L. See www.egi.com for more information on the Company.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGSEWSMFFMSEDM
12
Date   Source Headline
28th Mar 20147:00 amRNSAnnual Financial Report
26th Feb 20147:00 amRNSFinal Results
21st Feb 20147:00 amRNSRegulatory Approval
25th Nov 20137:00 amRNSTrading Statement
1st Oct 20137:00 amRNSAcquisition
4th Sep 20137:00 amRNSAppointment of Non-executive Director
4th Sep 20137:00 amRNSHalf Yearly Report
23rd Jul 20137:00 amRNSTrading Update
29th May 20137:00 amRNSCollaboration with Hitachi
17th May 20137:04 amRNSProduct Launch
8th Apr 20133:41 pmRNSHolding(s) in Company
5th Apr 20133:31 pmRNSHolding(s) in Company
3rd Apr 20137:01 amRNSEGI commences trading on AIM
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.